. 2016 Aug 5;7(37):59417–59428. doi: 10.18632/oncotarget.11086

Table 3. Immunogenicity of native HLA-B0702 restricted peptides, number of responding mice/number of vaccinated mice, peptides in grey were withdrawn from the selection process, MAGE-A3₂₇₄ was selected for further optimization because the immune response it generated was very weak (see Figure 3).

Antigen	Peptide	Sequence	Immunogenicity
Her2/neu	Her2/neu₇₆₀	SPKANKEIL	4/9
	Her2/neu₂₄₆	GPKHSDCLA	0/9
	Her2/neu₁₀₆₉	APRSPLAPS	5/7
	Her2/neu₁₁₅₁	SPREGPLPA	1/3
MAGE-A1; MAGE-A4	MAGE-A1₂₆₇	GPRALAETS	0/3
MAGE-A2; MAGE-A6	MAGE-A2₂₇₄	GPRALIETS	0/3
MAGE-A3, MAGE-A12	MAGE-A3₂₇₄	GPRALVETS	2/3*
CEA	CEA₁₈₈	SPRLQLSND	0/3
HSP70	HSP70₄₆₆	APRGVPQIEV	3/3
P53	P53₆₃	APRMPEAAP	3/3

Table 3. Immunogenicity of native HLA-B*0702 restricted peptides, number of responding mice/number of vaccinated mice, peptides in grey were withdrawn from the selection process, *MAGE-A3274 was selected for further optimization because the immune response it generated was very weak (see Figure 3).